Background The risk for thromboembolisms in nonsmall cell lung cancer (NSCLC) patients
is increased and often requires treatment or prophylaxis with direct oral anticoagulants …

Abstract Background Small-molecule inhibitors (SMIs) have revolutionised the treatment of
non-small cell lung cancer (NSCLC). However, SMI-induced drug–drug interactions (DDIs) …

Cancer-associated thrombosis (CAT) is the second leading cause of death in cancer
patients after tumor progression. The treatment of CAT is challenging because of a high risk …

Background Use of direct oral anticoagulants (DOACs) in patients with cancer remains
suboptimal due to the concern regarding potential drug-drug interactions (DDIs) with …

Venous thromboembolism (VTE) is a common complication in patients with cancer and is
associated with poor prognosis. Low-molecular-weight heparins (LMWHs) are the standard …

Patients with cancer are at high risk of developing venous thromboembolism (VTE).
Although the recommended low molecular weight heparins (LMWHs) are more effective …

Patients with cancer have a 6–7-fold higher risk of venous thromboembolism (VTE) as
compared with non-cancer patients. Effective and safe anticoagulation for the prevention …

Venous thromboembolism (VTE) is a frequent complication of cancer, and management of
cancer-associated thrombosis (CAT) is challenging due to increased risks of bleeding and …

Direct oral anticoagulants for the treatment of acute venous thromboembolism in patients with
cancer: a meta-analysis of randomised controlled trials | European Respiratory Society Skip …

Numerous randomized clinical trials and more than a decade of experience have clearly
established direct oral anticoagulants (DOACs), also known as non–vitamin K antagonist …